Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Public ClinicalTrials.gov record NCT00390611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Study identification
- NCT ID
- NCT00390611
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Paclitaxel Drug
- Sorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2006
- Primary completion
- Jun 30, 2012
- Completion
- Mar 31, 2014
- Last update posted
- Dec 21, 2014
2006 – 2014
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northeast Arkansas Clinic | Jonesboro | Arkansas | 72401 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Gulfcoast Oncology Associates | St. Petersburg | Florida | 33705 | — |
| Medical College of Georgia Cancer Specialists | Augusta | Georgia | 30912 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Consortium | Bethesda | Maryland | 20817 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Grand Rapids Clinical Oncology Program | Grand Rapids | Michigan | 49503 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| South Carolina Oncology Associates, PA | Columbia | South Carolina | 29210 | — |
| Tennessee Valley Clinical Research | Chattanooga | Tennessee | 37411 | — |
| Family Cancer Center | Collierville | Tennessee | 38017 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | — |
| Peninsula Cancer Center | Newport News | Virginia | 23601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00390611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2014 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00390611 live on ClinicalTrials.gov.